(Q24185912)

ORCID Public Data File 2021

author name string

Larry C Lands

series ordinal

1

0 references

publication date

7 April 2016

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

The role of inflammation in the pathophysiology of CF lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Current understanding of the inflammatory process in cystic fibrosis: onset and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Macrolide antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

7 January 2021

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

7 January 2021

High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

7 January 2021

Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001505.PUB4

7 January 2021